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We thank Dr Gostner and colleagues for their comments on our paper “One-Carbon 
Metabolism Biomarkers and Cognitive Decline in the Very Old: The Newcastle 85+ Study” (1). In 
their letter to the Editor, Dr Gostner and colleagues highlight the complexity of the underlying 
metabolic processes and conclude that “The question arises whether the inclusion of tryptophan 
metabolism measurements would allow better conclusions about relevant biochemical pathways and 
neurotransmitters in the development of cognitive decline in the elderly than homocysteine and 1-
carbon (1-C) metabolism can do, because alterations of the latter metabolic pathways are most 
probably secondary to immune activation and inflammation.” (2). While further measurements would 
be beneficial in elucidating the link between 1-C metabolism and cognition, we think that it is 
unlikely that immune activation and inflammation are the main causes for altered 1-C metabolism.  
Convincing data for the association between B vitamins, homocysteine and cognition is 
provided by the VITACOG studies (3) which showed that the rate of brain atrophy was 53% slower in 
those supplemented  with vitamin B6, vitamin B12 and folic acid but only in those with raised total 
homocysteine (tHcy) concentrations (>13 mmol/L) at baseline (3). In a following study from this 
group, the cerebral atrophy was pinpointed to the grey matter regions (including the medial temporal 
lobe) which are specifically susceptible to Alzheimer’s disease (4). It was concluded that the decline in 
brain atrophy in older adults with mild cognitive impairment could be slowed through normalising 
tHcy concentrations by B vitamin supplementation (3,4).  
Dr Gostner and colleagues draw attention to the potential importance of tryptophan and its 
metabolites in the development of cognitive impairment. In the Newcastle 85+ Study, we did not 
measure concentrations of tryptophan or its metabolites (e.g. kynurenine) (5). However, we have 
explored the effects of diet (6,7), the sole source of tryptophan in humans, on cognitive function in the 
Newcastle 85+ Study (8). Granic A et al found that dietary patterns (DP) high in red meat (including 
processed red meats), potato and gravy (DP1), or butter (DP3) were associated with poor cognition 
but not with the rate of cognitive decline in very old adults (8). Participants with DP1 and DP3 had 
worse Standardized Mini-Mental State Examination (SMMSE) scores (β = 0.09, P = 0.01 and β = 
0.08, P = 0.02, respectively) than those with a low meat diet (DP2) after adjustment for key 
confounders. Participants in DP1 and DP3 also had worse reaction time (β = 0.04, P = 0.002 and β = 
0.03, P = 0.03, respectively) and focused attention (β = 0.02, P = 0.01 and β = 0.02, P = 0.03, 
respectively) (8).  
As Gostner JM et al mentioned, inflammation is of great relevance to neurodegeneration and 
cognitive function (2). Using the Newcastle 85+ Study, Granic A et al derived inflammatory biomarker 
profiles by principal component analysis (PCA) explaining 70% of the total variance in seven baseline 
biomarkers (basal and stimulated interleukin-6, basal tumour necrosis factor α, tHcy, high sensitivity 
c-reactive protein and albumin) (9). Using data from the Newcastle 85+ Study, we are planning to 
investigate the relationship between the inflammatory biomarker profiles and cognitive function in the 
very old. In addition, in the final growth models used in our paper (1) we explored the relationship 
between tHcy concentrations and global cognition (SMMSE) and attention (assessed by CDR System) 
(1), and further adjusted for high-sensitivity C-Reactive Protein (hs-CRP). Inclusion of this 
inflammatory biomarker (hs-CRP) did not change the results for the SMMSE or for scores from the 
CDR System reflecting focussed attention, sustained attention and fluctuations in attention. This 
suggests that the inverse association between tHcy and cognition that we observed in the very old may 
be independent of inflammation. However, we reserve our conclusions about this relationship until the 
investigation of the associations between inflammatory biomarker profiles and cognitive decline in 
the Newcastle 85+ Study is completed.   
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